<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.102018</article-id><article-id pub-id-type="publisher-id">ACM-34085</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200200000_55826618.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  麝香通心滴丸对冠状动脉慢血流的改善作用
  Effect of Shexiang Tongxin Dropping Pills on Coronary Slow Flow
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>伟良</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>颖</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>晶晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>招海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沈</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>妍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>放</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>绍兴市人民医院(浙江大学绍兴医院)，心血管内科，浙江 绍兴</addr-line></aff><aff id="aff3"><addr-line>绍兴市人民医院(浙江大学绍兴医院)，临床药学科，浙江 绍兴</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>21</day><month>01</month><year>2020</year></pub-date><volume>10</volume><issue>02</issue><fpage>111</fpage><lpage>117</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探索麝香通心滴丸对冠状动脉慢血流患者的临床作用。方法：选择2018年3月至2019年2月因心绞痛就诊于我院并通过冠状动脉造影确诊为冠状动脉慢血流的70例住院患者，随机分为麝香通心滴丸组(35例)和对照组(35例)。两组均按照冠心病诊疗常规予以抗血小板、抗动脉硬化等治疗，麝香通心滴丸组在上述基础上加服麝香通心滴丸(冠脉造影术中即刻舌下含服175 mg，造影术后口服70 mg tid，连续服用6月)。造影术中测定含服麝香通心滴丸前及含服5分钟后患者的冠状动脉微循环阻力指数(Index of microcirculatory resistance，IMR)，术前及连续服药6个月后应用加拿大心血管病学会(CCS)心绞痛分级及西雅图心绞痛量表(SAQ)评估两组患者治疗前后心绞痛严重程度及评分。结果：两组患者治疗前的CCS分级、SAQ评分、IMR值的差异无统计学意义(P &lt; 0.05)。患者含服麝香通心滴丸5分钟后其IMR值(27.9 &#177; 7.7)较含服前(30.7 &#177; 5.6)明显改善(P &lt; 0.05)，也明显低于对照组(30.9 &#177; 4.8)，差距有统计学意义(P &lt; 0.05)；两组患者治疗6个月后的CCS分级降低(P &lt; 0.05)，SAQ评分升高(P &lt; 0.05)，且上述指标麝香通心滴丸组患者的改善效果较对照组更为显著(P &lt; 0.05)。结论：麝香通心滴丸可改善冠状动脉慢血流患者的微血管功能并明显减少心绞痛的发作。
    Objective: To explore the clinical impact of Shexiang Tongxin dropping pills (STDP) on patients with coronary slow flow (CSF). Methods: From March 2018 to February 2019, 70 inpatients with angina pectoris who were admitted to our hospital and diagnosed with CSF by coronary angiography were randomly divided into the STDP group (35 cases) and the control group (35 cases). Both groups were treated with anti-platelet and anti-arteriosclerosis according to the routine of coronary heart disease diagnosis and treatment, and the STDP group was given STDP on the above basis (175 mg was taken sublingually immediately during coronary angiography, and 70 mg tid was taken orally after angiography for 6 months). Index of microcirculatory resistance (IMR) was measured before and after 5 minutes of sublingual administration during coronary angiography. The severity and score of angina pectoris before and after treatment were assessed by the Canadian Cardiovascular Society (CCS) angina grading and Seattle Angina Questionnaire (SAQ). Results: There was no significant difference in CCS grade, SAQ score, IMR value between the two groups before treatment (p &lt; 0.05). The IMR value (27.9 &#177; 7.7) was significantly improved 5 minutes after sublingual STDP than before the administration (30.7 &#177; 5.6) (P &lt; 0.05) and also significantly lower than that in the control group (30.9 &#177; 4.8) (p &lt; 0.05). The CCS grade was decreased (p &lt; 0.05) and the SAQ score was increased (p &lt; 0.05) in the two groups after 6 months of treatment. Moreover, the improvement effect of the above index was more significant in the patients with STDP group than in the control group (p &lt; 0.05). Conclusions: Shexiang Tongxin drop pills can improve the microvascular function of patients with slow coronary blood flow and significantly reduce the attack of angina pectoris. 
  
 
</p></abstract><kwd-group><kwd>麝香通心滴丸，冠状动脉慢血流，冠状动脉微血管功能，心绞痛, Shexiang Tongxin Dropping Pills</kwd><kwd> Coronary Slow Flow</kwd><kwd> Coronary Microvascular Dysfunction</kwd><kwd> 
Angina Pectoris</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>麝香通心滴丸对冠状动脉慢血流的改善作用<sup> </sup></title><p>唐伟良<sup>1*</sup>，吴颖<sup>2*</sup>，赵晶晶<sup>1</sup>，郑招海<sup>1</sup>，沈静<sup>1</sup>，周妍<sup>1</sup>，彭放<sup>1#</sup></p><p><sup>1</sup>绍兴市人民医院(浙江大学绍兴医院)，心血管内科，浙江 绍兴</p><p><sup>2</sup>绍兴市人民医院(浙江大学绍兴医院)，临床药学科，浙江 绍兴</p><disp-formula id="hanspub.34085-formula8"><graphic xlink:href="//html.hanspub.org/file/5-1571138x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年1月2日；录用日期：2020年1月15日；发布日期：2020年1月22日</p><disp-formula id="hanspub.34085-formula9"><graphic xlink:href="//html.hanspub.org/file/5-1571138x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探索麝香通心滴丸对冠状动脉慢血流患者的临床作用。方法：选择2018年3月至2019年2月因心绞痛就诊于我院并通过冠状动脉造影确诊为冠状动脉慢血流的70例住院患者，随机分为麝香通心滴丸组(35例)和对照组(35例)。两组均按照冠心病诊疗常规予以抗血小板、抗动脉硬化等治疗，麝香通心滴丸组在上述基础上加服麝香通心滴丸(冠脉造影术中即刻舌下含服175 mg，造影术后口服70 mg tid，连续服用6月)。造影术中测定含服麝香通心滴丸前及含服5分钟后患者的冠状动脉微循环阻力指数(Index of microcirculatory resistance，IMR)，术前及连续服药6个月后应用加拿大心血管病学会(CCS)心绞痛分级及西雅图心绞痛量表(SAQ)评估两组患者治疗前后心绞痛严重程度及评分。结果：两组患者治疗前的CCS分级、SAQ评分、IMR值的差异无统计学意义(P &lt; 0.05)。患者含服麝香通心滴丸5分钟后其IMR值(27.9 &#177; 7.7)较含服前(30.7 &#177; 5.6)明显改善(P &lt; 0.05)，也明显低于对照组(30.9 &#177; 4.8)，差距有统计学意义(P &lt; 0.05)；两组患者治疗6个月后的CCS分级降低(P &lt; 0.05)，SAQ评分升高(P &lt; 0.05)，且上述指标麝香通心滴丸组患者的改善效果较对照组更为显著(P &lt; 0.05)。结论：麝香通心滴丸可改善冠状动脉慢血流患者的微血管功能并明显减少心绞痛的发作。</p><p>关键词 :麝香通心滴丸，冠状动脉慢血流，冠状动脉微血管功能，心绞痛</p><disp-formula id="hanspub.34085-formula10"><graphic xlink:href="//html.hanspub.org/file/5-1571138x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1571138x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1571138x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>冠心病是危害全球人类生命健康的疾病，传统意义上的冠心病指冠状动脉粥样硬化引起冠状动脉狭窄或闭塞而导致的心肌缺氧、缺血甚至坏死的疾病。近年来，随着冠状动脉造影(Coronary Angiography, CAG)的开展与普及，非狭窄性的冠心病发病率不断增加，其中包括冠状动脉慢血流(Coronary Slow Flow, CSF)。CSF指CAG显示冠状动脉无明显狭窄而造影剂到达远端一根或多根血管延迟的现象 [<xref ref-type="bibr" rid="hanspub.34085-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref2">2</xref>]。在所有行CAG的患者中，CSF占5.5% [<xref ref-type="bibr" rid="hanspub.34085-ref3">3</xref>]。CSF患者多表现为反复发作的心绞痛，甚至可发展为恶性心律失常、缺血性心肌病、急性冠脉综合征以及心源性猝死等严重不良事件 [<xref ref-type="bibr" rid="hanspub.34085-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref7">7</xref>]。然而，CSF的发病机制暂不明确，多项研究表明冠状动脉微血管功能障碍(Coronary Microvascular Dysfunction, CMD)与CSF密切相关 [<xref ref-type="bibr" rid="hanspub.34085-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.34085-ref9">9</xref>]。因此，探索能有效抑制或改善CMD的途径及治疗方式，对预防及延缓CSF的发生发展有重要意义。</p><p>麝香通心滴丸是治疗心血管疾病的常用中成药，具有改善微循环、降低炎性因子、改善内皮功能、稳定斑块等功能。现有研究表明麝香通心滴丸有助于改善患者CSF，但临床报道相对偏少，且已报道的研究存在评价指标受研究者主观影响较大等问题。为进一步客观探索麝香通心滴丸对CSF的作用及潜在机制，本研究采用冠状动脉微循环阻力指数(Index of microcirculatory resistance, IMR)探索麝香通心滴丸即刻含服对CSF患者微血管功能的影响，并进一步评价该药物口服6个月后对CSF患者的临床疗效。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 冠状动脉慢血流的诊断标准 [<xref ref-type="bibr" rid="hanspub.34085-ref1">1</xref>]</title><p>1) 心外膜冠状动脉无粥样硬化性狭窄(狭窄 &lt; 40%)；2) 由校正的TIMI血流帧数(Corrected TIMI Frame Count，CTFC)计法评价，冠状动脉中左前降支、回旋支及右冠状动脉3支血管有1支血管TIMI血流帧数 &gt; 27帧(回放速度为30帧/s)；3) 至少一支远端心外膜血管出现造影剂延迟显像。并除外以下情况：1) 冠状动脉无复流现象；2) 冠状动脉扩张；3) 冠状动脉血栓栓塞；4) 外源性血管收缩剂的使用等。</p></sec><sec id="s4_2"><title>2.2. 纳入及排除标准</title><p>纳入标准：符合CSF诊断标准、年龄 ≥ 18岁、患者本人自愿参与临床试验并签署知情同意书。排除标准：心力衰竭、急性心肌梗死、冠状动脉成形术后、瓣膜性心脏病、结缔组织病、心肌病、自身免疫性疾病、近期外科手术、贫血、感染、肿瘤及其他重要脏器或全身疾病。</p></sec><sec id="s4_3"><title>2.3. 一般资料</title><p>选择2018年3月~2019年2月因心绞痛就诊于浙江大学绍兴医院(绍兴市人民医院)并行冠状动脉造影确诊为CSF的住院患者70例，男性37例，女性33例，年龄18~75岁，平均年龄54.2 &#177; 11.6岁。将入选患者随机分为麝香通心滴丸组(35例)和对照组(35例)。麝香通心滴丸组男性18例，女性17例，平均年龄55.5 &#177; 10.8岁；对照组男性19例，女性16例，平均年龄53.7 &#177; 12.4岁。两组患者的性别、年龄、吸烟史、既往史、生命体征、冠状动脉微循环阻力指数(Index of microcirculatory resistance，IMR)及用药情况的差异无统计学意义(P &gt; 0.05)。本临床实验经浙江大学绍兴医院伦理委员会同意，伦理审查批件编号：2017伦审论第023号。所有患者均签署知情同意书。</p></sec><sec id="s4_4"><title>2.4. 治疗方法</title><p>常规治疗：对照组和麝香通心滴丸组患者均常规服用瑞舒伐他汀钙片(5 mg qn，阿斯利康公司)、阿司匹林(100 mg qd，拜耳公司)、氯吡格雷(75 mg qd，赛诺菲公司)。合并高血压、糖尿病、高脂血症的患者给予降压、降糖、降脂治疗。</p><p>麝香通心滴丸组患者在常规治疗的基础上加用麝香通心滴丸，方法如下：即时服用：在第一次行冠状动脉造影并测定IMR后立即舌下含服麝香通心滴丸(175 mg once)，5分钟后再次测定患者的IMR值。长期口服：冠状动脉造影术后连续口服麝香通心滴丸(70 mg tid) 6个月。</p><p>对照组：在第一次行冠状动脉造影并测定IMR后含服常温生理盐水5 ml，5分钟后再次测定患者的IMR值。术后除常规治疗外无其他附加治疗方案。</p></sec><sec id="s4_5"><title>2.5. 观察指标及检测方法</title><p>1) 生化指标检测：两组患者均于第一次行冠状动脉造影前及最后一次行冠状动脉造影前的清晨留取空腹外周静脉血液标本10 ml，3000 rpm离心10 min后取上清，置于−80℃保存，检测空腹血糖、总胆固醇(TC)、低密度脂蛋白(LDL)、甘油三酯(TG)及超敏C反应蛋白(CRP)。</p><p>2) IMR检测方法：两组患者治疗前后均用雅培动脉生理检测仪(Radi Analyzer TM)和一根0.014 in (1 in = 2.54 cm)头端带有压力–温度感受器的软指引导丝检测IMR。1) 将不带侧孔的6F指引导管置于冠状动脉口，压力导丝送至导5.1生化指标检测：两组患者均于第一次行冠状动脉造影前及最后一次行冠状动脉造影前的清晨留取空腹外周静脉血液标本10 ml，3000 rpm离心10 min后取上清，置于−80℃保存，检测空腹血糖、总胆固醇(TC)、低密度脂蛋白(LDL)、甘油三酯(TG)及超敏C反应蛋白(CRP)。</p><p>3) 心绞痛程度评估：两组患者在治疗前及治疗6个月后均按照加拿大心血管学会心绞痛分级(Canadian Cardiovascular Society, CCS) [<xref ref-type="bibr" rid="hanspub.34085-ref10">10</xref>] 及西雅图心绞痛量表(Seattle angina questionnaire，SAQ量表) [<xref ref-type="bibr" rid="hanspub.34085-ref11">11</xref>] 进行心绞痛程度的评估。</p></sec><sec id="s4_6"><title>2.6. 统计学方法</title><p>应用SPSS24.0软件进行统计学数据分析，计量资料用均数&#177;标准差表示，采用t检验进行比较；计数资料采用卡方检验进行比较。P &lt; 0.05代表数据差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 一般资料比较</title><p>治疗前，两组患者的一般资料，如年龄、性别、吸烟史、高血压、糖尿病及体重指数均无明显差异(见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Patients’ general dat</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >对照组(n = 35)</th><th align="center" valign="middle" >麝香通心滴丸组(n = 35)</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁， x &#175; &#177; S )</td><td align="center" valign="middle" >53.7 &#177; 12.4</td><td align="center" valign="middle" >55.5 &#177; 10.8</td></tr><tr><td align="center" valign="middle" >性别(男/女，例)</td><td align="center" valign="middle" >19/16</td><td align="center" valign="middle" >18/17</td></tr><tr><td align="center" valign="middle" >吸烟史(例/%)</td><td align="center" valign="middle" >12/34.3%</td><td align="center" valign="middle" >10/28.6%</td></tr><tr><td align="center" valign="middle" >高血压(例/%)</td><td align="center" valign="middle" >13/37.1%</td><td align="center" valign="middle" >11/31.4%</td></tr><tr><td align="center" valign="middle" >糖尿病(例/%)</td><td align="center" valign="middle" >8/22.9%</td><td align="center" valign="middle" >7/20.0%</td></tr><tr><td align="center" valign="middle" >体重指数(Kg/m<sup>2</sup>， x &#175; &#177; S )</td><td align="center" valign="middle" >24.2 &#177; 5.3</td><td align="center" valign="middle" >24.5 &#177; 4.8</td></tr></tbody></table></table-wrap><p>表1. 患者一般资料</p></sec><sec id="s5_2"><title>3.2. 实验室检测指标</title><p>两组患者治疗前实验室检测指标(见表2)，如LDL、TC、TG、CRP及空腹血糖之间的差异无统计学意义(p &gt; 0.05)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Baseline of blood lipid, inflammatory index and blood glucose in patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >对照组(N = 35)</th><th align="center" valign="middle" >麝香通心滴丸组(N = 35)</th></tr></thead><tr><td align="center" valign="middle" >LDL (mmol/L)</td><td align="center" valign="middle" >3.4 &#177; 1.0</td><td align="center" valign="middle" >3.5 &#177; 0.7</td></tr><tr><td align="center" valign="middle" >Tc (mmol/L)</td><td align="center" valign="middle" >2.5 &#177; 0.7</td><td align="center" valign="middle" >2.4 &#177; 0.5</td></tr><tr><td align="center" valign="middle" >Tg (mmol/L)</td><td align="center" valign="middle" >5.1 &#177; 0.6</td><td align="center" valign="middle" >5.2 &#177; 0.8</td></tr><tr><td align="center" valign="middle" >CRP (UG/ML)</td><td align="center" valign="middle" >3.7 &#177; 1.2</td><td align="center" valign="middle" >3.6 &#177; 1.6</td></tr><tr><td align="center" valign="middle" >空腹血糖(mmol/L)</td><td align="center" valign="middle" >5.6 &#177; 0.9</td><td align="center" valign="middle" >5.8 &#177; 1.2</td></tr></tbody></table></table-wrap><p>表2. 患者血脂、炎症指标、血糖等检测结果的基线对照</p></sec><sec id="s5_3"><title>3.3. 治疗前后IMR</title><p>两组患者治疗前与即刻治疗后IMR比较(见表3)。与治疗前相比，对照组患者IMR (30.9 &#177; 4.8)与治疗前(30.5 &#177; 5.2)无明显差异。麝香通心滴丸组患者治疗后IMR (27.9 &#177; 7.7)较治疗前明显降低(30.7 &#177; 5.6)，差异有统计学意义(p &lt; 0.05)。同时，与对照组治疗后相比，麝香通心滴丸组患者治疗后IMR也明显降低，差异有统计学意义(p &lt; 0.05)。上述结果表明，麝香通心滴丸舌下含服具有即刻改善患者CSF的临床作用，这对改善CSF患者冠状动脉微循环灌注有积极意义。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Changes of IMR before and after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >对照组(n = 35)</th><th align="center" valign="middle" >麝香通心滴丸组(n = 35)</th></tr></thead><tr><td align="center" valign="middle" >治疗前IMR</td><td align="center" valign="middle" >30.5 &#177; 5.2</td><td align="center" valign="middle" >30.7 &#177; 5.6</td></tr><tr><td align="center" valign="middle" >治疗后IMR</td><td align="center" valign="middle" >30.9 &#177; 4.8</td><td align="center" valign="middle" >27.9 &#177; 7.7<sup>*#</sup></td></tr></tbody></table></table-wrap><p>表3. 患者治疗前后IMR的变化情况</p><p>注：与本组治疗前比较，*P &lt; 0.05；与对照组同期比较，#P &lt; 0.05。</p></sec><sec id="s5_4"><title>3.4. CCS分级及SAQ评分</title><p>两组患者治疗前与治疗6个月后CCS心绞痛分级及SAQ评分比较(见表4)。对照组患者治疗前CCS分级为2.7 &#177; 0.6，SAQ评分为251.4 &#177; 52.6，而治疗后其CCS分级降低为2.3 &#177; 0.3，SAQ评分升高为306.9 &#177; 49.8，差异有统计学意义(p &lt; 0.05)。麝香通心滴丸组患者治疗后CCS分级为1.1 &#177; 0.4，较治疗前(2.6 &#177; 0.5)明显下降，其治疗后SAQ评分为372.1 &#177; 54.9，较治疗前(247.8 &#177; 55.3)明显升高，差异有统计学意义(p &lt; 0.01)。与对照组治疗后相比，麝香通心滴丸组患者治疗后CCS分级明显下降，SAQ评分明显升高(p &lt; 0.05)。上述结果表明，常规治疗与常规治疗联合麝香通心滴丸治疗均有助于改善患者临床心绞痛发作情况，且加用麝香通心滴丸的联合治疗较常规治疗能更明显地改善患者心绞痛症状。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Scores of patients’ CCS classification and SAQ before and after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >CCS分级</th><th align="center" valign="middle" >SAQ评分</th></tr></thead><tr><td align="center" valign="middle" >对照组(n = 35)</td><td align="center" valign="middle" >治疗前 治疗后</td><td align="center" valign="middle" >2.7 &#177; 0.6 2.3 &#177; 0.3<sup>*</sup></td><td align="center" valign="middle" >251.4 &#177; 52.6 306.9 &#177; 49.8<sup>*</sup></td></tr><tr><td align="center" valign="middle" >麝香通心滴丸组(n = 35)</td><td align="center" valign="middle" >治疗前 治疗后</td><td align="center" valign="middle" >2.6 &#177; 0.5 1.1 &#177; 0.4<sup>**#</sup></td><td align="center" valign="middle" >247.8 &#177; 55.3 372.1 &#177; 54.9<sup>**#</sup></td></tr></tbody></table></table-wrap><p>表4. 治疗前后患者CCS分级及SAQ评分结果</p><p>注：与本组治疗前比较，*P &lt; 0.05，**P &lt; 0.01；与对照组同期比较，#P &lt; 0.05。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>麝香通心滴丸是治疗心血管疾病的常用中成药，是芳香开窍、活血化瘀、化痰通络的代表方，由古方至宝丹及六神丸化裁而来。其主要作用机制为改善微循环、降低炎性因子、改善内皮功能、抗凋亡、抑制RAAS系统、稳定斑块、改善心肌纤维化 [<xref ref-type="bibr" rid="hanspub.34085-ref12">12</xref>]。整体研究表明，麝香通心滴丸可改善心肌梗死小鼠的冠脉微循环功能 [<xref ref-type="bibr" rid="hanspub.34085-ref13">13</xref>]，王胜煌教授 [<xref ref-type="bibr" rid="hanspub.34085-ref14">14</xref>] 等也通过冠脉造影CTFC计数发现麝香通心滴丸具有即刻改善CSF的作用。然而，目前对麝香通心滴丸干预CSF的临床研究总体较少，仅涉及4篇相关论文报道、335例患者 [<xref ref-type="bibr" rid="hanspub.34085-ref15">15</xref>]，且存在CTFC计数受研究者主观影响较大、评价手段不客观等问题。</p><p>目前临床上，评判微循环功能的指标主要有血流储备分数(Flow Fractional Reserve，FFR)与IMR。FFR指冠脉最大充盈时血流与基础状态血流之比，主要测量 &gt; 400 &#236;m的心外膜大血管。然而，临床上发现，FFR对心外膜血管和异常的微循环两者带来的血流影响无法区别，且易受干扰，实用性与重复性差 [<xref ref-type="bibr" rid="hanspub.34085-ref16">16</xref>]。与之相较，IMR代表的是在峰值血流通过的条件下最小的微循环阻力，其优点在于其独立于心外膜系统，不受血流动力学影响及重复性强。因此，本研究选用IMR不仅可以判断患者服药前后的微循环功能状态，又可进一步证实CMD在CSF发展过程中的作用。</p><p>本研究发现，CAG术中舌下含服麝香通心滴丸可在短时间内明显降低CSF患者IMR值。这表明麝香通心滴丸含服具有快速吸收、快速起效、有助于即刻改善冠状动脉微循环功能。这一结果与当前所报道的研究结果总体一致 [<xref ref-type="bibr" rid="hanspub.34085-ref14">14</xref>]，也符合麝香通心滴丸主要成分的药理作用。麝香通心滴丸的主要成分为人工麝香、人参茎叶总皂苷、蟾酥、丹参、人工牛黄、熊胆粉和冰片。现代药理研究发现，方中麝香有扩张血管、增加心输出量、抗炎等诸多作用 [<xref ref-type="bibr" rid="hanspub.34085-ref17">17</xref>]。其主要有效成分麝香酮对缺血、缺氧等导致的细胞损伤具有明显的保护作用 [<xref ref-type="bibr" rid="hanspub.34085-ref18">18</xref>]。人参皂苷可通过刺激内皮细胞依赖的血管舒张实现降压，并通过改善血管内皮细胞功能、抗氧化应激等作用对心血管系统疾病起到防治作用 [<xref ref-type="bibr" rid="hanspub.34085-ref19">19</xref>]。丹参的有效成分丹参酮IIA具有增加心肌局部组织血流量、抗血栓形成、抗动脉粥样硬化、抗炎等作用 [<xref ref-type="bibr" rid="hanspub.34085-ref20">20</xref>]。熊胆粉具有抗动脉粥样硬化、抗炎、抗氧化应激等作用 [<xref ref-type="bibr" rid="hanspub.34085-ref21">21</xref>]。综上，麝香通心滴丸依托其各组分的扩血管、改善血管内皮功能、抗炎抗氧化等作用，综合发挥其对CSF的改善作用。</p><p>此外，本研究进一步探索了麝香通心滴丸长期服用对CSF患者临床症状的改善作用，结果发现，连续口服麝香通心滴丸6个月可明显降低CSF患者心绞痛CCS分级并增加SAQ评分，从而提高CSF患者的生活质量。这为临床上治疗CSF探索了一条新的尝试途径。目前临床上对CSF的治疗主要包括扩张微血管、改善内皮功能、抑制炎症因子及氧化应激，常用药物如硝酸酯类、钙离子通道阻滞剂、他汀类、非选择性β受体阻滞剂等 [<xref ref-type="bibr" rid="hanspub.34085-ref22">22</xref>]。然而西药通常只通过单向机制发挥作用，且因依从性较差而未能得到规律用药，研究也发现上述药物并不能明显改变CSF患者冠脉血流情况。与之相较，麝香通心滴丸为我们展示了祖国传统医学的独特一面：重视系统论、整体论，通过不同组分多通道多机制发挥改善CSF作用，为患者改善其临床症状、提高其生活质量提供有效的治疗手段。</p></sec><sec id="s7"><title>5. 总结</title><p>麝香通心滴丸组与对照组两组患者治疗前的CCS分级、SAQ评分、IMR值的差异无统计学意义(P &lt; 0.05)。患者含服麝香通心滴丸5分钟后其IMR值(27.9 &#177; 7.7)较含服前(30.7 &#177; 5.6)明显改善(P &lt; 0.05)，也明显低于对照组(30.9 &#177; 4.8)，差距有统计学意义(P &lt; 0.05)；两组患者治疗6个月后的CCS分级降低(P &lt; 0.05)，SAQ评分升高(P &lt; 0.05)，且上述指标麝香通心滴丸组患者的改善效果较对照组更为显著(P &lt; 0.05)。研究结果提示，麝香通心滴丸有助于通过减轻CSF而改善患者心脏微循环功能、减少心肌缺血的发作，是值得临床探索、尝试改善CSF的有效途径。</p></sec><sec id="s8"><title>基金项目</title><p>本研究受浙江省医药卫生科研项目(2018KY827)、浙江省中医药科学研究基金项目(B类) (2018ZB130)资助。</p></sec><sec id="s9"><title>文章引用</title><p>唐伟良,吴 颖,赵晶晶,郑招海,沈 静,周 妍,彭 放. 麝香通心滴丸对冠状动脉慢血流的改善作用Effect of Shexiang Tongxin Dropping Pills on Coronary Slow Flow[J]. 临床医学进展, 2020, 10(02): 111-117. https://doi.org/10.12677/ACM.2020.102018</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34085-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ghaffari, S., et al. (2017) Clinical and Laboratory Predictors of Coronary Slow Flow in Coronary Angiography. Perfusion, 32, 13-19. https://doi.org/10.1177/0267659116659918</mixed-citation></ref><ref id="hanspub.34085-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tambe, A.A., et al. (1972) Angina Pectoris and Slow Flow Velocity of Dye in Coronary Arteries: A New Angiographic Finding. American Heart Journal, 84, 66-71. https://doi.org/10.1016/0002-8703(72)90307-9</mixed-citation></ref><ref id="hanspub.34085-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hawkins, B.M., et al. (2012) Coronary Slow Flow—Prevalence and Clinical Correlations. Circulation Journal, 76, 936-942. https://doi.org/10.1253/circj.CJ-11-0959</mixed-citation></ref><ref id="hanspub.34085-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Beltrame, J.F. (2012) Defining the Coronary Slow Flow Phenomenon. Circulation Journal, 76, 818-820.  
https://doi.org/10.1253/circj.CJ-12-0205</mixed-citation></ref><ref id="hanspub.34085-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X. and Nie, S.P. (2011) The Coronary Slow Flow Phenomenon: Characteristics, Mechanisms and Implications. Cardiovascular Diagnosis and Therapy, 1, 37-43.</mixed-citation></ref><ref id="hanspub.34085-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Oktay, V. and Arat, O.A. (2016) Coronary Slow Flow. Turk Kardiyoloji Dernegi Arsivi, 44, 193-195.  
https://doi.org/10.5543/tkda.2016.72429</mixed-citation></ref><ref id="hanspub.34085-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Heusch, G., Skyschally, A. and Kleinbongard, P. (2018) Coronary Microembolization and Microvascular Dysfunction. International Journal of Cardiology, 258, 17-23. https://doi.org/10.1016/j.ijcard.2018.02.010</mixed-citation></ref><ref id="hanspub.34085-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Esmaeili, N.A., et al. (2016) Opium Addiction as an Independent Risk Factor for Coronary Microvascular Dysfunction: A Case-Control Study of 250 Consecutive Patients with Slow-Flow Angina. International Journal of Cardiology, 219, 301-307. https://doi.org/10.1016/j.ijcard.2016.06.034</mixed-citation></ref><ref id="hanspub.34085-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yin, P., Wang, S.G. and Zhang, A.Y. (2016) Relationship between Slow Coronary Flow and Coronary Microcirculatory Dysfunction in Relevant Patients. Chinese Circulation Journal, 31, 555-558.</mixed-citation></ref><ref id="hanspub.34085-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Campeau, L. (1976) Letter: Grading of angina pectoris. Circulation, 54, 522-523.  
https://doi.org/10.1161/circ.54.3.947585</mixed-citation></ref><ref id="hanspub.34085-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Spertus, J.A., Winder, J.A., Dewhurst, T.A., et al. (1994) Monitoring the Quality of Life in Patients with Coronary Artery Disease. American Journal of Cardiology, 74, 1240-1244. https://doi.org/10.1016/0002-9149(94)90555-X</mixed-citation></ref><ref id="hanspub.34085-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">陈照云, 黄兴, 周立华, 刘庆乐, 张翠萍, 李娇, 李雪倩. 麝香通心滴丸药物作用机制和药物靶点的研究进展[J]. 河南中医, 2019, 39(7): 1117-1121.</mixed-citation></ref><ref id="hanspub.34085-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.D., Shi, S.L., Li, N., et al. (2017) Protective Effects of Shexiang Tongxin Dropping Pill on Microcirculation Dysfunction in Myocardial Infarction Mice Induced by LPS and Its Mechanism. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular, 15, 2969-2972.</mixed-citation></ref><ref id="hanspub.34085-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S.H., Chu, L., Xu, Z., et al. (2014) Effect of Shexiang Tongxin Dropping Pills on the Immediate Blood Flow of Patients with Coronary Slow Flow. Chinese Journal of Integrated Traditional and Western Medicine, 34, 1425-1431.</mixed-citation></ref><ref id="hanspub.34085-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">韩松洁, 张晓雨, 张立晶, 等. 麝香通心滴丸对PCI术后患者慢血流的临床证据评价[J]. 世界科学技术-中医药现代化, 2018, 20(10): 1772-1776.</mixed-citation></ref><ref id="hanspub.34085-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ford, T.J., Corcoran, D., Sidik, N., McEntegart, M. and Berry, C. (2018) Coronary Microvascular Dysfunction: Assessment of Both Structure and Function. Journal of the American College of Cardiology, 72, 584-586.  
https://doi.org/10.1016/j.jacc.2018.03.545</mixed-citation></ref><ref id="hanspub.34085-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">郝吉福, 程怡. 麝香的药理学研究概况[J]. 时珍国医国药, 2004, 15(4): 248-249.</mixed-citation></ref><ref id="hanspub.34085-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">姜涛, 等. 麝香酮对脑损伤大鼠脑保护作用的研究[J]. 中国中西医结合杂志, 2016, 36(6): 724-728.</mixed-citation></ref><ref id="hanspub.34085-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">陈梅卿, 李卫华, 石桂秀. 人参皂苷Rb1对心血管系统的药理作用研究进展[J]. 医学综述, 2015, 21(3): 506-509.</mixed-citation></ref><ref id="hanspub.34085-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">陈芬燕, 郭韧, 张毕奎. 丹参酮IIA的心血管药理作用研究进展[J]. 中国中药杂志, 2015, 40(9): 1649-1653.</mixed-citation></ref><ref id="hanspub.34085-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">熊敏琪, 等. 熊胆粉在麝香通心滴丸抗动脉粥样硬化中的作用机制研究[J]. 中国中西医结合杂志, 2015, 35(9): 1083-1089.</mixed-citation></ref><ref id="hanspub.34085-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">徐朝, 王胜煌. 冠状动脉慢血流药物治疗研究进展[J]. 中国循环杂志, 2015, 30(1): 81-83.</mixed-citation></ref></ref-list></back></article>